FDA Halts Pediatric R/R AML Phase 1 SC-DARIC33 Trial: Latest Update

The FDA has placed a clinical hold on the phase 1 PLAT-08 trial, which is evaluating SC-DARIC33 as a treatment for pediatric patients and young adults with relapsed/refractory acute myeloid leukemia (AML). The hold was initiated due to a grade 5 serious adverse effect (SAE) that occurred during the study. The developers of SC-DARIC33 are working with the FDA to investigate the cause of the toxicity and make protocol changes to continue the trial.

In a presentation at the 2023 American Society of Gene & Cell Therapy Annual Meeting, investigators shared data on SC-DARIC33 from the PLAT-08 study. One patient showed expansion of SC-DARIC33 cells in the skin, leading to the destruction of leukemic cells. Another patient showed SC-DARIC33 cell expansion in the blood, resulting in a reduction in leukemic burden. These findings suggest the potential of SC-DARIC33 as a T-cell therapy approach for AML.

The PLAT-08 trial is an open-label, non-randomized phase 1 study that aims to assess the safety and manufacturing success of SC-DARIC33. The primary endpoint is the occurrence of adverse events, and the secondary endpoint is AML response in patients with CD33-positive leukemia. Patients aged 30 or younger with relapsed/refractory CD33-positive leukemia were eligible for enrollment in the trial if they met certain criteria.

 


Transplant News
Transplant News

Transplant News brings you the news and content that matters to the transplant community. From patient stories, to the latest in transplant innovation, Transplant News is your window into the world of transplantation.